

## CLAIMS:

1. An antibody specific for proliferating/angiogenic human endothelial cells.
2. An antibody according to claim 1 which is specific for proliferating/angiogenic human umbilical vein endothelial cells (HUVEC) or human umbilical artery endothelial cells (HUAEC).
3. An antibody according to claim 1 or claim 2 which is a monoclonal antibody.
4. A hybridoma cell line producing a monoclonal antibody according to claim 3.
5. An antibody-conjugate comprising an antibody specific for proliferating/angiogenic human endothelial cells, having a toxin material or label conjugated thereto.
6. An antibody-conjugate according to claim 5, wherein said antibody is specific for proliferating/angiogenic human umbilical vein endothelial cells (HUVEC) or human umbilical artery endothelial cells (HUAEC).
7. An antibody-conjugate according to claim 5 or claim 6, wherein said antibody is a monoclonal antibody.
8. An antibody-conjugate according to claim 5, wherein said antibody is conjugated to a cytotoxic material.
9. An antibody-conjugate according to claim 8, wherein said cytotoxic material is ricin A chain, diphtheria toxin, Pseudomonas exotoxin A or idarubicin.

08815933-031397

- 13 -

10. An antibody-conjugate according to claim 5, wherein said antibody is conjugated to a radioisotope label.
11. An antibody-conjugate according to claim 10, wherein said radioisotope label is technetium-99m.
12. A therapeutic composition for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease, comprising an antibody according to any of claims 1 to 3 or an antibody-conjugate according to any of claims 5 to 11, together with a pharmaceutically acceptable carrier or diluent.
13. A method for inhibition of angiogenesis in a patient, including angiogenesis associated with the growth of solid tumours or with proliferative retinopathies, which comprises administration to said patient of an inhibition-effective amount of an antibody according to any of claims 1 to 3 or an antibody-conjugate according to any of claims 5 to 11.
14. Use of an antibody according to any of claims 1 to 3 or an antibody-conjugate according to any of claims 5 to 11, in the manufacture of a pharmaceutical composition for inhibition of angiogenesis in a patient, including angiogenesis associated with the growth of solid tumours or with proliferative retinopathies.
15. A method for treatment of angiogenesis-dependent disease in a patient, which comprises administration to said patient of a therapeutic-effective amount of an antibody according to any of claims 1 to 3 or an antibody-conjugate according to any of claims 5 to 11.
16. Use of an antibody according to any of claims 1 to 3 or an antibody-conjugate according to any of claims 5 to 11, in the manufacture of a pharmaceutical composition for treatment of angiogenesis-dependent disease.

add  
B1  
add  
C1

03815933-03139